Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bendamustine + lenalidomide + rituximab (Teva Pharmaceutical)
- Development stage
- Unknown
- Lead developer
- Georgetown University
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
BLR-CLL is a combination chemoimmunotherapy regimen consisting of the alkylating agent bendamustine, the immunomodulatory drug lenalidomide, and the anti-CD20 monoclonal antibody rituximab. Developed as an investigator-initiated regimen at Georgetown University, it was evaluated in a Phase I dose-escalation study for patients with relapsed or refractory B-cell lymphoid malignancies, including chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL). The regimen combines the cytotoxic effects of bendamustine-induced DNA cross-linking with the immunomodulatory, anti-proliferative, and anti-angiogenic activities of lenalidomide, alongside rituximab-mediated antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) against CD20-positive B-cells.
- Other names
- Bendamustine-Lenalidomide-RituximabB-LR
02
Targets
CD20 (B-lymphocyte antigen CD20)DNAIKZF3 (Zinc finger protein Aiolos)IKZF1 (Ikaros family zinc finger protein 1)CRBN (Cereblon)
Beyond the preview
Go deeper on bendamustine + lenalidomide + rituximab (Teva Pharmaceutical).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bendamustine + lenalidomide + rituximab (Teva Pharmaceutical).